US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Maze Therapeutics / Equity Capital Markets

<ul>
<li>The company has a potential blockbuster treatment for a certain type of chronic kidney disease  affecting millions of Americans.</li>
<li>The company could raise up to $132.6m if priced at the high-end of the range which would value the company at $728m.</li>
<li>The sector vastly underperformed in the aftermarket and is looking to start 2025 on the right foot.</li>
</ul>


The company has a potential blockbuster treatment for a certain type of chronic kidney disease  affecting millions of Americans.
The company could raise up to $132.6m if priced at the high-end of the range which would value the company at $728m.
The sector vastly underperformed in the aftermarket and is looking to start 2025 on the right foot.


Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

<ul>
<li>Currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease</li>
<li>Lead candidate initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose their first patient in the first quarter of 2025</li>
<li>We anticipate this company to set terms (share size, price range) in the next week for a late January / early February debut.</li>
</ul>


Currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease
Lead candidate initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose their first patient in the first quarter of 2025
We anticipate this company to set terms (share size, price range) in the next week for a late January / early February debut.


Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

United States

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic diseases, including obesity.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Maze Therapeutics (MAZE US)

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

​Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

​A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut...

IPO Boutique

Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut...